Commun Biol April 2023 PMID 37029216

A high throughput bispecific antibody discovery pipeline.

Aude I Segaliny, Jayapriya Jayaraman, Xiaoming Chen, Jonathan Chong, Ryan Luxon, Audrey Fung, Qiwei Fu, Xianzhi Jiang, Rodrigo Rivera, Xiaoya Ma, Ci Ren, Jan Zimak, Per Niklas Hedde, Yonglei Shang, George Wu

Full text PDF Download social card

Mentions

Peak: 5 in Sep 2021

across 3 sources since Sep 2021

Extended reach

151,753

potential audience

Total likes

Video views

Mentions per month

Sep 2021 – Aug 2023

Where it's discussed

X / Twitter8 posts
Blogs2 articles
YouTube1 videos

AI synopsis

What people are saying

The social discussions reflect strong support and excitement, with posts describing the platform's ability to screen millions of variants rapidly and its potential to advance cancer immunotherapy. Phrases like 'significantly increase development speed' and 'game changer' demonstrate high interest and perceived impact, while some users engage with technical aspects, indicating moderate engagement.

AgreementModerate agreement

Most discussions express support and enthusiasm for the publication, highlighting its potential to accelerate antibody discovery.

InterestHigh interest

Posts show high interest, with several enthusiastic mentions of the platform's capabilities and potential applications.

EngagementModerate engagement

Some comments delve into technical details and implications, indicating moderate engagement.

ImpactModerate impact

The discussion reflects an expectation of meaningful impact, as posts emphasize the platform's speed and potential to revolutionize therapeutics.

Abstract in brief

The text describes a new high-throughput, single-cell based screening method for discovering bispecific antibodies (BsAbs), which are promising cancer immunotherapies but currently limited by inefficient discovery processes.
Using a model bispecific T cell engager (BiTE), the platform can screen up to 1.5 million variants per run and successfully identify rare functional clones present at very low frequencies (as low as 0.0008%).
This method not only accelerates the discovery of effective immunotherapeutics but also provides insights into how different antibody designs influence functionality, helping to establish principles for designing better BsAbs in the future.]

Read the full abstract

All mentions

High-Throughput Platform for Bispecific Antibody Discovery

Social RTCL TV · Aug 4, 2023 35 views

Single Cell papers

@scell_papers · X

A high throughput bispecific antibody discovery pipeline https://t.co/978VfotPHU

Apr 11, 2023 · 1 like · 11,492 followers View post →

Awakened Guardian

@Tian_A1 · X

Apr 8, 2023 · 2,028 followers View post →

Weian Zhao

@zhao_weian · X

Apr 7, 2023 · 1 like · 21 followers View post →

Ah-Ram Kim

@ahramkim1128 · X

A high throughput bispecific antibody discovery pipeline https://t.co/qwsnHIrtC6

Sep 9, 2021 · 283 followers View post →

Engineering Papers

@eng_papers · X

A high throughput bispecific antibody discovery pipeline https://t.co/6PCef9vpjg

Sep 8, 2021 · 45 followers View post →

Skatiq

@Skatiq3 · X

RT @biorxivpreprint: A high throughput bispecific antibody discovery pipeline https://t.co/NLqw0tTjiW #bioRxiv

Sep 8, 2021 · 1 share · 274 followers View post →

bioRxiv Bioengineering

@bioRxiv_bioE · X

A high throughput bispecific antibody discovery pipeline https://t.co/E8Uw7PFKmj #biorxiv_bioE

Sep 8, 2021 · 208 followers View post →

bioRxiv

@biorxivpreprint · X

A high throughput bispecific antibody discovery pipeline https://t.co/NLqw0tTjiW #bioRxiv

Sep 8, 2021 · 2 likes · 1 share · 137,364 followers View post →